LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report ...
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid ...
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – ...
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well ...
Want to start earning interest? You can open an account with Voyager today! The traditional lending market has been flipped on its head by blockchain technology. From decentralized, instant and ...
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback